Compare CCM & CVRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CCM | CVRX |
|---|---|---|
| Founded | 1997 | 2000 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Medical/Nursing Services | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.3M | 17.9M |
| IPO Year | 2009 | 2021 |
| Metric | CCM | CVRX |
|---|---|---|
| Price | $3.59 | $0.61 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $1.65 |
| AVG Volume (30 Days) | 12.4K | ★ 778.0K |
| Earning Date | 11-27-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 23.02 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $56,651,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $3.66 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 10.45 |
| 52 Week Low | $2.79 | $0.61 |
| 52 Week High | $6.80 | $10.28 |
| Indicator | CCM | CVRX |
|---|---|---|
| Relative Strength Index (RSI) | 49.72 | 20.39 |
| Support Level | $3.28 | N/A |
| Resistance Level | $4.10 | $1.55 |
| Average True Range (ATR) | 0.26 | 0.14 |
| MACD | -0.00 | -0.04 |
| Stochastic Oscillator | 47.31 | 2.30 |
Concord Medical Services Holdings Ltd operates radiotherapy and diagnostic imaging centers in China. The company is involved in the leasing of radiotherapy and diagnostic imaging equipment, provision of management services to hospitals, medicine sales, and provision of premium cancer and proton treatment services. The company has two operating segments, including network and hospital. Geographically, the company derives revenue from PRC.
CVRx Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its proprietary platform technology, Barostim, is designed to leverage the power of the brain to address the imbalance of the Autonomic Nervous System, which causes heart failure and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy which in turn triggers an autonomic response to the heart. The majority of revenue is derived from the USA market.